Sparassis latifolia and exercise training as complementary medicine mitigated the 5-fluorouracil potent side effects in mice with colorectal cancer: bioinformatics approaches, novel monitoring pathological metrics, screening signatures, and innovative management tactic.
5-Fluorouracil
AOM
Biomarkers
Colorectal Cancer
DSS
Diagnosis
Exercise
Palliative care
Sparassis latifolia
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
23
12
2023
accepted:
12
04
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
18
4
2024
Statut:
epublish
Résumé
Prompt identification and assessment of the disease are essential for reducing the death rate associated with colorectal cancer (COL). Identifying specific causal or sensitive components, such as coding RNA (cRNA) and non-coding RNAs (ncRNAs), may greatly aid in the early detection of colorectal cancer. For this purpose, we gave natural chemicals obtained from Sparassis latifolia (SLPs) either alone or in conjunction with chemotherapy (5-Fluorouracil to a mouse colorectal tumor model induced by AOM-DSS. The transcription profile of non-coding RNAs (ncRNAs) and their target hub genes was evaluated using qPCR Real-Time, and ELISA techniques. MSX2, MMP7, ITIH4, and COL1A2 were identified as factors in inflammation and oxidative stress, leading to the development of COL. The hub genes listed, upstream regulatory factors such as lncRNA PVT1, NEAT1, KCNQ1OT1, SNHG16, and miR-132-3p have been discovered as biomarkers for prognosis and diagnosis of COL. The SLPs and exercise, effectively decreased the size and quantity of tumors. This effect may be attributed to the modulation of gene expression levels, including MSX2, MMP7, ITIH4, COL1A2, PVT1, NEAT1, KCNQ1OT1, SNHG16, and miR-132-3p. Ultimately, SLPs and exercise have the capacity to be regarded as complementing and enhancing chemotherapy treatments, owing to their efficacious components.
Sections du résumé
BACKGROUND
BACKGROUND
Prompt identification and assessment of the disease are essential for reducing the death rate associated with colorectal cancer (COL). Identifying specific causal or sensitive components, such as coding RNA (cRNA) and non-coding RNAs (ncRNAs), may greatly aid in the early detection of colorectal cancer.
METHODS
METHODS
For this purpose, we gave natural chemicals obtained from Sparassis latifolia (SLPs) either alone or in conjunction with chemotherapy (5-Fluorouracil to a mouse colorectal tumor model induced by AOM-DSS. The transcription profile of non-coding RNAs (ncRNAs) and their target hub genes was evaluated using qPCR Real-Time, and ELISA techniques.
RESULTS
RESULTS
MSX2, MMP7, ITIH4, and COL1A2 were identified as factors in inflammation and oxidative stress, leading to the development of COL. The hub genes listed, upstream regulatory factors such as lncRNA PVT1, NEAT1, KCNQ1OT1, SNHG16, and miR-132-3p have been discovered as biomarkers for prognosis and diagnosis of COL. The SLPs and exercise, effectively decreased the size and quantity of tumors.
CONCLUSIONS
CONCLUSIONS
This effect may be attributed to the modulation of gene expression levels, including MSX2, MMP7, ITIH4, COL1A2, PVT1, NEAT1, KCNQ1OT1, SNHG16, and miR-132-3p. Ultimately, SLPs and exercise have the capacity to be regarded as complementing and enhancing chemotherapy treatments, owing to their efficacious components.
Identifiants
pubmed: 38637796
doi: 10.1186/s12935-024-03328-y
pii: 10.1186/s12935-024-03328-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
141Informations de copyright
© 2024. The Author(s).
Références
Polymers (Basel). 2022 Jan 28;14(3):
pubmed: 35160537
Hum Cell. 2021 Jul;34(4):1051-1065
pubmed: 33997944
Bioinformatics. 2009 Aug 1;25(15):1898-904
pubmed: 19439566
NPJ Syst Biol Appl. 2020 Jul 31;6(1):23
pubmed: 32737302
Acta Histochem. 2022 Feb;124(2):151844
pubmed: 35045377
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
Nutrients. 2021 Jan 06;13(1):
pubmed: 33419097
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Nat Methods. 2014 Jun;11(6):599-600
pubmed: 24874569
Nucleic Acids Res. 2023 Jul 5;51(W1):W168-W179
pubmed: 37166973
BMC Genomics. 2018 Jan 2;19(1):1
pubmed: 29291715
BMC Cancer. 2017 Jan 3;17(1):1
pubmed: 28049525
J Physiol Biochem. 2020 Feb;76(1):1-12
pubmed: 31808077
Cancer Sci. 2020 Sep;111(9):3142-3154
pubmed: 32536012
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Int J Biol Macromol. 2019 Sep 15;137:1112-1120
pubmed: 31271800
Br J Sports Med. 2016 Jul;50(13):796-803
pubmed: 26719503
Nucleic Acids Res. 2013 Jan;41(Database issue):D983-6
pubmed: 23175614
Sci Rep. 2015 Aug 21;5:13413
pubmed: 26292924
Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Oncol Lett. 2020 Apr;19(4):3173-3180
pubmed: 32256813
Nucleic Acids Res. 2023 Jan 6;51(D1):D1373-D1380
pubmed: 36305812
Tech Coloproctol. 2019 Jan;23(1):3-13
pubmed: 30701345
Cell Metab. 2018 Jan 9;27(1):10-21
pubmed: 29056514
Cancer Biother Radiopharm. 2017 Jun;32(5):149-160
pubmed: 28622036
J Proteome Res. 2019 Feb 1;18(2):623-632
pubmed: 30450911
BMC Palliat Care. 2020 Jan 3;19(1):1
pubmed: 31900221
Thorac Cancer. 2020 Aug;11(8):2112-2124
pubmed: 32500672
Gastroenterology. 2020 Jan;158(2):447-452
pubmed: 31622620
Front Neurol. 2022 Feb 17;13:806344
pubmed: 35250815
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Antioxidants (Basel). 2023 Apr 09;12(4):
pubmed: 37107276
Cardiol Clin. 2019 Nov;37(4):399-405
pubmed: 31587781
Crit Rev Oncol Hematol. 2022 Feb;170:103578
pubmed: 35007701
Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251
pubmed: 32484539
Ann Surg Oncol. 2010 Apr;17(4):959-66
pubmed: 20082144
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646
pubmed: 36370105
Int J Biol Macromol. 2023 Mar 31;232:123299
pubmed: 36649865
Front Immunol. 2022 Jun 17;13:887048
pubmed: 35784334
Mol Med Rep. 2019 Dec;20(6):5002-5020
pubmed: 31638221
Nat Biotechnol. 2006 Sep;24(9):1115-22
pubmed: 16964225
J Clin Oncol. 2007 Oct 10;25(29):4569-74
pubmed: 17876008
Nucleic Acids Res. 2016 Jan 4;44(D1):D1045-53
pubmed: 26481362
Acta Biochim Pol. 2022 Jun 6;69(2):371-377
pubmed: 35667086
Food Chem. 2011 Jul 15;127(2):791-6
pubmed: 23140737
BMC Cancer. 2022 Jan 3;22(1):1
pubmed: 34979993
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Anticancer Res. 2023 Jan;43(1):19-24
pubmed: 36585181
Nutrients. 2019 Sep 02;11(9):
pubmed: 31480668
Redox Biol. 2021 Nov;47:102144
pubmed: 34562873
Lab Invest. 2019 Jan;99(1):118-127
pubmed: 30206311
Database (Oxford). 2023 Mar 4;2023:
pubmed: 36869839
Cancer Lett. 2020 Jan 28;469:246-255
pubmed: 31678167
J Clin Oncol. 2000 Jan;18(1):136-47
pubmed: 10623704
Int Immunopharmacol. 2021 Oct;99:108022
pubmed: 34339961
Cancer Biol Ther. 2019;20(4):524-536
pubmed: 30395767
Cancer Sci. 2019 Oct;110(10):3098-3109
pubmed: 31389121
J Cell Biochem. 2019 Dec;120(12):19358-19370
pubmed: 31490563
Nucleic Acids Res. 2023 Jan 6;51(D1):D199-D207
pubmed: 36321659
Sci Rep. 2021 Jul 14;11(1):14456
pubmed: 34262080
Genome Biol. 2019 Jan 3;20(1):1
pubmed: 30606230
Nucleic Acids Res. 2021 Jan 8;49(D1):D969-D980
pubmed: 33045741
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
Environ Res. 2023 Dec 1;238(Pt 2):117168
pubmed: 37742751
Nucleic Acids Res. 2023 Jan 6;51(D1):D186-D191
pubmed: 36330950
Front Immunol. 2020 Nov 27;11:574046
pubmed: 33329538
Bioinformatics. 2022 Mar 4;38(6):1761-1763
pubmed: 34935889
Comput Struct Biotechnol J. 2019 Jan 25;17:177-185
pubmed: 30809322
J Cheminform. 2011 Jan 07;3(1):1
pubmed: 21214931
J Mol Neurosci. 2023 Mar;73(2-3):171-184
pubmed: 36631703